{"organizations": [], "uuid": "61eee7ecf7bdbc3bf4909eeb8e4276f89a00c6c2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cas-group-delivers-letter-to-the-s/brief-cas-group-delivers-letter-to-the-stockholders-of-aviragen-idUSFWN1PJ11R", "country": "US", "domain_rank": 408, "title": "BRIEF-CAS Group Delivers Letter To The Stockholders Of Aviragen", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-24T16:17:00.000+02:00", "replies_count": 0, "uuid": "61eee7ecf7bdbc3bf4909eeb8e4276f89a00c6c2"}, "author": "", "url": "https://www.reuters.com/article/brief-cas-group-delivers-letter-to-the-s/brief-cas-group-delivers-letter-to-the-stockholders-of-aviragen-idUSFWN1PJ11R", "ord_in_thread": 0, "title": "BRIEF-CAS Group Delivers Letter To The Stockholders Of Aviragen", "locations": [], "entities": {"persons": [{"name": "avi", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "digirad corp", "sentiment": "none"}, {"name": "ragen reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "aviragen therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 24, 2018 / 2:18 PM / in 4 minutes BRIEF-CAS Group Delivers Letter To The Stockholders Of Aviragen Reuters Staff \nJan 24 (Reuters) - Aviragen Therapeutics Inc: \n* CAS GROUP DELIVERS LETTER TO THE STOCKHOLDERS OF AVIRAGEN \n* CAS GROUP SAYS PROPOSED MERGER BETWEEN AVIRAGEN AND VAXART NOT IN BEST INTERESTS OF STOCKHOLDERS OF AVIRAGEN \n* CAS GROUP - “BELIEVE VAXART‘S TRUE VALUE IS LOWER THAN THAT INDICATED IN PROPOSED MERGER” \n* CAS GROUP SAYS “‍BELIEVE VAXART‘S TRUE VALUE IS LOWER THAN THAT INDICATED IN PROPOSED MERGER AND THAT VAXART IS NOT READY TO BE A PUBLIC COMPANY”​ \n* CAS GROUP - DIGIRAD CORP, EAST HILL MANAGEMENT, THOMAS CLAY (COLLECTIVELY CAS GROUP) OWN ABOUT 8.3 PERCENT OF OUTSTANDING AVIRAGEN SHARES \n* CAS GROUP - HAS NOMINATED A SLATE OF DIRECTORS FOR AVIRAGEN‘S BOARD Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-24T16:17:00.000+02:00", "crawled": "2018-01-24T16:33:54.009+02:00", "highlightTitle": ""}